Chikungunya vaccine candidate developed by codon pair de-optimization
Chikungunya vaccine candidate developed by codon pair de-optimization
批准号:
9296049
负责人:
Yutong Song
金额:
$23.84万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-06-14 至 2019-05-31
关键词:
AedesAffectAfricanAlgorithmsAlphavirusAmericasAnalgesicsAnimal ModelAntibodiesArbovirusesAreaArthralgiaAttenuatedAttenuated VaccinesBreathingCaribbean regionCell LineCenters for Disease Control and Prevention (U.S.)Central AmericaChikungunya virusClinicalCodon NucleotidesComputer AssistedComputersCountryCulicidaeDangerousnessDataDengueDengue VirusDiagnosisDiseaseDisease OutbreaksEngineeringEpidemicEuropeanExanthemaExposure toFamilyFetusFeverFrequenciesGenesGenomeHumanHuman BitesHuman poliovirusIndiaIndian Ocean IslandsIndividualIndonesiaInfectionIslandLaboratoriesLanguageLeadMalaysiaMammalsMedicineMothersMusMyalgiaNamesNauseaNon-Steroidal Anti-Inflammatory AgentsPainPharmaceutical PreparationsPharmacotherapyProteinsRNARNA VirusesRiskScientistSingaporeSouth AmericaSoutheastern AsiaSymptomsTanganyikaTanzaniaThailandTimeTogaviridaeUnited StatesUnited States National Institutes of HealthVaccinesVariantViralVirusVirus DiseasesWalkingadaptive immune responseaerosolizedattenuationbasechikungunyadesigndesign and constructioninfluenzavirusnew technologynonhuman primatenovelpathogenpreventsoutheast Asiansucklingtissue culturevaccine candidate
中文摘要
摘要
基孔肯雅病毒(Chikungenya Virus,CHIKV)是Togaviridae家族中的一种甲型病毒,是一种重要的
近年来在世界各地传播的危险的病毒病原体。CHIKV致病原因
基孔肯雅热和严重的关节痛,可能会持续几个月。就像登革热病毒
(DENV),CHIKV也是一种节肢动物传播的病毒(虫媒病毒)。目前,没有获得许可的疫苗或
基孔肯雅病毒的药物可供人类使用。
我们最近开发了一种新技术,它基于理性的、计算机辅助的基因
被称为合成减毒病毒工程(SAVE)的设计,以减弱正负
链RNA病毒(脊髓灰质炎病毒、流感病毒、登革热病毒)通过重新编码它们的基因组来
介绍不受欢迎的密码子对。这些密码子对去优化的病毒都是成功的
在组织培养和动物模型中都是弱化的。在这里,我们建议延长节省时间
这种新出现的和危险的病毒病原体基孔肯雅病毒的方法,以追求
一株减毒病毒株的分离。在计算机的帮助下,专门定制了
算法我们将重新编码CHIKV的基因组,使其包含大片段
(编码NSP4、E2、E1)的密码子对在哺乳动物中不受欢迎。基于
我们之前的研究预计,这些重新编码的Chik病毒将被类似地减毒和
将作为可能的活疫苗候选者
英文摘要
Abstract
Chikungunya virus (CHIKV), an alphavirus in the Togaviridae family, is an important and
dangerous viral pathogen that has spread around the world in recent years. CHIKV causes
chikungunya fever and severe arthralgia that may persist for several months. Like Dengue Virus
(DENV), CHIKV is also an arthropod-borne virus (arbovirus). Currently, no licensed vaccine or
drug is available for human use for Chikungunya virus.
We have recently developed a novel technology that is based on rational, computer-aided gene
design, termed Synthetic Attenuated Virus Engineering (SAVE), to attenuate plus and minus
strand RNA viruses (poliovirus, influenza virus dengue virus) by recoding their their genomes to
introduce unfavored codon pairs. Those codon pair deoptimized viruses were all successfully
attenuated both in tissue culture and in an animal model. Here, we propose to extend the SAVE
approach to this emerging and dangerous viral pathogen, Chikungunya virus, to pursue the
isolation of an attenuated viral strain. With the aid of computers and specifically tailored
algorithms we will recode the genome of CHIKV such that it will contain large segments
(encoding either the proteins nsP4, E2, E1) of codon pairs dis-favored in mammals. Based on
our previous studies we expect that these recoded CHIK viruses will be similarly attenuated and
will serve as possible live vaccine candidates
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金